You are here: Industry Insights > Biosimilar

News List

The Rise of Biosimilars: Regulatory Pathways and Market Outlook Nurah Ekhlaque
September 19, 2025
Biosimilars are changing the way healthcare systems manage the high cost of advanced medicines.
The Role of Biosimilars Suzanne Elvidge
February 12, 2025
Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.
Global Drug Innovation Trend and Its Market Landscape Shruti Talashi
September 25, 2024
The creation of novel medications, treatments, and medical equipment that improve patient care and treatment results or outcomes is referred to as pharmaceutical innovation.
What’s the known so far with Medicines & Good Manufacturing Practices? Shruti Talashi
May 16, 2023
Be it a pharmaceutical or bio-pharmaceutical, both are regulated by the FDA, US. And it is mandatory for both kinds of manufacturing companies to follow the current Good manufacturing practices (cGMP) inprocess of getting certified from USFDA.
The Coming Successor and the Ending Humira Yi/PharmaSources
March 01, 2023
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
Which Will Market the First Chinese-produced Trastuzumab Biosimilar: Sunshine Guojian or Henlius? PharmaSources/Dopine
June 15, 2020
HER2-positive breast cancer has a high degree of malignancy and fast progression. Trastuzumab is the standard first-line regimen for adjuvant, neoadjuvant and metastatic cancer treatment of HER2-positive breast cancer.
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab) B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion PharmaSources
July 24, 2023
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.
Participants Dosed on Adessia in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa PharmaSources
March 07, 2023
Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and overseas.
Biosimilar Tocilizumab Injection approved for marketing www.nmpa.com
January 16, 2023
Biosimilar Tocilizumab Injection approved for marketing.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page